Gene · 833
Papers4,113
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
261 to 280 of 4,113
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Aminoacyl-tRNA synthetase interactions in SARS-CoV-2 infection. | Biochem Soc Trans | 2023 | 38108455 | PubTator, text mining | PubMed |
| The 4-1BBζ costimulatory domain in chimeric antigen receptors enhances CD8+ T-cell functionality following T-cell receptor stimulation. | Cancer Cell Int | 2023 | 38105188 | PubTator, text mining | PubMed |
| Harnessing immunotherapy for brain metastases: insights into tumor-brain microenvironment interactions and emerging treatment modalities. | J Hematol Oncol | 2023 | 38104104 | PubTator, text mining | PubMed |
| Chimeric antigen receptors enable superior control of HIV replication by rapidly killing infected cells. | PLoS Pathog | 2023 | 38100526 | PubTator, text mining | PubMed |
| Toxicities of CAR T-cell therapy: a review of current literature. | Ann Med Surg (Lond) | 2023 | 38098580 | PubTator, text mining | PubMed |
| Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. | Front Immunol | 2023 | 38098489 | PubTator, text mining | PubMed |
| Strategies for HIV-1 suppression through key genes and cell therapy. | Front Med (Lausanne) | 2023 | 38093984 | PubTator, text mining | PubMed |
| DIALing-up the preclinical characterization of gene-modified adoptive cellular immunotherapies. | Front Immunol | 2023 | 38090585 | PubTator, text mining | PubMed |
| Broadening the horizon: potential applications of CAR-T cells beyond current indications. | Front Immunol | 2023 | 38090582 | PubTator, text mining | PubMed |
| Multi-dimensional role of gangliosides in modulating cancer hallmarks and their prospects in targeted cancer therapy. | Front Pharmacol | 2023 | 38089042 | PubTator, text mining | PubMed |
| Potentiation of natural killer cells to overcome cancer resistance to NK cell-based therapy and to enhance antibody-based immunotherapy. | Front Immunol | 2023 | 38077389 | PubTator, text mining | PubMed |
| Allo Beta Cell transplantation: specific features, unanswered questions, and immunological challenge. | Front Immunol | 2023 | 38077372 | PubTator, text mining | PubMed |
| Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. | Mol Ther Oncolytics | 2023 | 38075241 | PubTator, text mining | PubMed |
| Developing New Strategies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma. | J Clin Med | 2023 | 38068428 | PubTator, text mining | PubMed |
| Unveiling the Immunogenicity of Ovarian Tumors as the Crucial Catalyst for Therapeutic Success. | Cancers (Basel) | 2023 | 38067396 | PubTator, text mining | PubMed |
| Chimeric Antigen Receptor-T Cell and Oncolytic Viral Therapies for Gastric Cancer and Peritoneal Carcinomatosis of Gastric Origin: Path to Improving Combination Strategies. | Cancers (Basel) | 2023 | 38067366 | PubTator, text mining | PubMed |
| Small Antibodies with Big Applications: Nanobody-Based Cancer Diagnostics and Therapeutics. | Cancers (Basel) | 2023 | 38067344 | PubTator, text mining | PubMed |
| Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity. | Signal Transduct Target Ther | 2023 | 38062078 | PubTator, text mining | PubMed |
| Deletion of the protein tyrosine phosphatase PTPN22 for adoptive T cell therapy facilitates CTL effector function but promotes T cell exhaustion. | J Immunother Cancer | 2023 | 38056892 | PubTator, text mining | PubMed |
| CAR-modified Cellular Therapies in Chronic Lymphocytic Leukemia: Is the Uphill Road Getting Less Steep? | Hemasphere | 2023 | 38044959 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/833/papers?page=14